REPL:NASDAQReplimune Group, Inc. Analysis

Replimune (REPL) is trading at $2.68, well below its 20‑day ($4.41), 50‑day ($6.33) and 200‑day ($7.12) simple moving averages, indicating a strong bearish price trend. The 14‑day RSI sits at 34.9, suggesting the stock is approaching oversold territory but not yet at a reversal point, while the MACD histogram remains negative, reinforcing bearish momentum. Volatility is extreme at roughly 346% over the past 30 days and beta is modest at 0.60, meaning price swings are large but somewhat insulated from broader market moves. The company has zero revenue, negative EBITDA and cash flow, and a trailing EPS of –$3.44, yet it holds $269 M in cash against $76 M of debt, giving a debt‑to‑equity of 36%, and trades at a price‑to‑book ratio of just 1.01, essentially at book value. Analyst consensus is “underperform” with a median price target of $2.00 and a mean of $3.50, while recent downgrades from Leerink, Wedbush and Jefferies reflect heightened skepticism.
The most material catalyst is the FDA’s complete response letter on the RP1 Biologics License Application, which introduces regulatory uncertainty for the lead oncolytic therapy. Coupled with recent analyst downgrades and a lack of commercial revenue, short‑term upside appears limited. However, the platform’s long‑term growth potential and a cash runway that could support further development keep a speculative, longer‑term case alive, provided the company can navigate the regulatory pathway and demonstrate clinical efficacy.